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Summary
Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailoring the intensity of therapy to
a patient’s risk of relapse. To determine whether gene expression profiling could enhance risk assignment, we used
oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients.
Distinct expression profiles identified each of the prognostically important leukemia subtypes, including T-ALL, E2A-PBX1,
BCR-ABL, TEL-AML1, MLL rearrangement, and hyperdiploid 50 chromosomes. In addition, another ALL subgroup was
identified based on its unique expression profile. Examination of the genes comprising the expression signatures provided
important insights into the biology of these leukemia subgroups. Further, within some genetic subgroups, expression
profiles identified those patients that would eventually fail therapy. Thus, the single platform of expression profiling should
enhance the accurate risk stratification of pediatric ALL patients.
Introduction approach was developed following the realization that pediatric
ALL is a heterogeneous disease consisting of various leukemia
subtypes that differ markedly in their response to chemotherapyPediatric acute lymphoblastic leukemia is one of the great suc-
cess stories of modern cancer therapy, with contemporary treat- (Pui and Evans, 1998). By tailoring the intensity of treatment to
a patient’s relative risk of relapse, patients are neither under-ment protocols achieving overall long-term event-free survival
rates approaching 80% (Schrappe et al., 2000; Silverman et al., treated or overtreated and are thus afforded the highest chance
for a cure.2001; Pui and Evans, 1998). This success has been achieved,
in part, by using risk-adapted therapy that involves tailoring the Critical to the success of this approach has been the accu-
rate assignment of individual patients to specific risk groups.intensity of treatment to each patient’s risk of relapse. This
S I G N I F I C A N C E
Acute lymphoblastic leukemia is a heterogeneous disease, with individual leukemia subtypes differing in their response to chemother-
apy. Identifying prognostically important leukemia subtypes is an imprecise process and is labor intensive, requiring the combined
expertise of hematologist/oncologist, pathologist, and cytogeneticist. Here we report results of expression profiling of leukemic blasts
from a large cohort of pediatric ALL patients. Our results demonstrate that expression profiling can not only accurately identify the
known prognostically important leukemia subtypes, but can further enhance our ability to assess a patient’s risk of failing therapy.
In addition, the identified expression profiles were found to include new diagnostic and subclassification markers, as well as candidates
against which novel therapeutics may be developed. Lastly, the analysis resulted in the identification of a new leukemia subtype.
These data suggest that in the near future, expression profiling will become an important diagnostic tool for the evaluation of pediatric
ALL patients.
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Although risk assignment is influenced by a variety of clinical probe sets in 327 leukemia samples; greater than 4  106 data
elements), we used an unsupervised two-dimensional hierarchi-and laboratory parameters, the genetic alterations that underlie
the pathogenesis of individual leukemia subtypes figure promi- cal clustering algorithm to group genes on the basis of similarity
in their pattern of expression over the samples. The same clus-nently in most classification schemes (Silverman et al., 2001;
Pui and Evans, 1998). Through systematic immunophenotyping tering method was also used to group the leukemia samples
on the basis of similarities in their pattern of genes expressedand cytogenetic analysis and the subsequent molecular cloning
of the genes targeted by the identified chromosomal re- (see Supplemental Data at http://www.stjuderesearch.org/data/
ALL1). Remarkably, this analysis clearly identified six major leu-arrangements, a number of genetically distinct leukemia sub-
types have been defined. These include B lineage leukemias kemia subtypes that corresponded to T-ALL, hyperdiploid
with50 chromosomes, BCR-ABL, E2A-PBX1, TEL-AML1, andthat contain t(9;22)[BCR-ABL], t(1;19)[E2A-PBX1], t(12;21)[TEL-
AML1], rearrangements in the MLL gene on chromosome 11, MLL gene rearrangement. Moreover, within the heterogeneous
collection of leukemias that were not assigned to one of theseband q23, or a hyperdiploid karyotype (i.e.,50 chromosomes),
and T lineage leukemias (T-ALL; Silverman et al., 2001; Pui and subtypes, a subgroup of 14 cases was identified that had a
distinct gene expression profile. These cases had normal,Evans, 1998). The underlying genetic lesions in these leukemia
subtypes influence the response to cytotoxic drugs. For exam- pseudodiploid, or hyperdiploid karyotypes and lacked any con-
sistent cytogenetic abnormality. The separation of the sevenple, leukemias that express the E2A-PBX1 fusion protein re-
spond poorly to conventional antimetabolite-based treatment leukemia subgroups was also seen using the multidimensional
scaling procedure of discriminant analysis with variance (DAV),but have cure rates approaching 80% when treated with more
intensive therapies (Raimondi et al., 1990; Hunger, 1996). Similarly, in which the data are reduced into component dimensions con-
sisting of linear combinations of discriminating genes (FigureBCR-ABL-expressing ALLs or infants with MLL rearrangements
have exceedingly poor cure rates with conventional chemother- 1A). For example, using the three component dimensions that
accounted for 72.8% of the variance of gene expression amongapy, and allogeneic hematopoietic stem cell transplantation with
an HLA-matched sibling donor has recently been shown to the subgroups, we were able to separate T-ALL (43 cases), E2A-
PBX1 (27 cases), TEL-AML1 (79 cases), and hyperdiploid50 (64improve outcome for patients with the former leukemia subtype
(Pui et al., 1991; Heerema et al., 1999; Arico et al., 2000; Biondi cases) from the remaining ALL subtypes (114 cases). Similarly,
using three different components that account for an additionalet al., 2000).
Unfortunately, the accurate assignment of patients to spe- 16.1% of the variance in gene expression, we could discriminate
cases with BCR-ABL (15 cases), MLL gene rearrangement (20cific risk groups is a difficult and expensive process, requiring
intensive laboratory studies including immunophenotyping, cy- cases), and the novel subgroup of ALL (14 cases).
We next used statistical methods to identify those genestogenetics, and molecular diagnostics (Pui and Evans, 1998;
Pui et al., 2001). Moreover, these diagnostic approaches require that best define the individual groups. The expression profiles
obtained using the top 40 genes per subgroup selected by athe collective expertise of a number of professionals, and al-
though this expertise is available at most major medical centers, chi-square metric are illustrated in Figure 1B, using the two-
dimensional hierarchical clustering algorithm. The chi-squareit is generally unavailable in developing countries. With the re-
cent development of DNA microarrays, it is now possible to metric is a statistical test of association and provides a rank-
ordered list of genes for each genetic subgroup. In this figure,take a genome-wide approach to leukemia classification (Perou
et al., 1999; Golub et al., 1999; Alizadeh et al., 2000). To deter- each column corresponds to a single leukemia sample and each
row represents the expression level of a single gene across themine whether the single platform of gene expression profiling
of leukemic blasts could replace conventional laboratory ap- sample set. The expression level of each gene relative to the
mean expression level across all samples is represented by aproaches while simultaneously enhancing prognostic criteria,
we utilized oligonucleotide microarrays to analyze the expres- color, with red representing expression above the mean and
green representing expression below the mean, and the inten-sion of over 12,600 genes in diagnostic leukemic blasts from
360 pediatric ALL patients. These studies demonstrate that ex- sity of the color corresponds to the magnitude of the deviation
from the mean. As shown, distinct groups of genes distinguishpression profiling is not only a robust approach for the accurate
identification of known lineage and molecular subtypes of ALL, cases defined by E2A-PBX1, MLL, T-ALL, hyperdiploid 50,
BCR-ABL, the novel subgroup, and TEL-AML1. In addition tobut also provides new insights into their underlying biology. In
addition, gene expression profiling allows the accurate identifi- these specific subgroups, 65 cases (20% of the total) were
identified that did not cluster into any of the leukemia subtypes.cation of some patients who are at a high risk for failing conven-
tional therapeutic approaches. The expression profiles of these latter cases varied markedly,
suggesting that they represent a heterogeneous group of leuke-
mias. Nearly identical results were obtained when the hierarchi-Results
cal clustering was performed with genes selected by other sta-
tistical metrics (see Supplemental Figures S14–S18 at http://Expression profiling of pediatric ALL—Biologic insights
To determine if gene expression profiling of leukemic cells could www.stjuderesearch.org/data/ALL1).
For T-ALL, two gene clusters were identified, one expressedidentify known biologic ALL subgroups, we analyzed 327 diag-
nostic bone marrow (BM) samples with Affymetrix oligonucleo- at high levels and one at low levels, that discriminated this
subtype from B lineage cases. By contrast, for each of thetide microarrays containing 12,600 probe sets. The distribution
of the individual prognostic subgroups within this data set is other leukemia subtypes, the top-ranked discriminating genes
primarily consisted of genes that were overexpressed within thedetailed in the Supplemental Data at http://www.stjuderesearch.
org/data/ALL1. specific leukemia subtype. It is important to emphasize that,
with the exception of T-ALL, the identified expression profilesIn an initial analysis of the gene expression data set (12,600
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Figure 1. Expression profiles of diagnostic bone marrow ALL blasts
A: Multidimensional scaling plot using DAV of the gene expression data from 327 diagnostic BM samples generated using the 10,991 probe sets that passed
the variance filter. Each case is represented by a sphere and is color-coded to indicate the specific genetic subgroup to which it belongs. Cases are
displayed in gene space with each component dimension consisting of a linear combination of genes that showed the greatest variance across the data
set. In the panel on the left, the space represents expression values of discriminant genes that correspond to 72.8% of the variance across the dataset,
whereas the panel on the right corresponds to three separate components that represents 16.1% of the total variance. B: Hierarchical clustering of 327
diagnostic ALL samples (columns) versus 271 genes (rows). The genes used in this analysis are the top 40 genes chosen by a chi-square statistic that are
most highly correlated with the seven specific class distinctions. Nine genes were identified as useful in discriminating more than one class, but each is
used only once in this analysis. The normalized expression value for each gene is indicated by a color, with red representing high expression and green
representing low expression, with the scale shown at the lower left.
do not represent a specific differentiation stage of the leukemic PBX1 genetic lesion and not the pre-B immunophenotype.
Moreover, we were unable to define expression profiles thatblasts. For example, although E2A-PBX1 is almost exclusively
found in ALLs with a pre-B cell immunophenotype (Hunger, were specific for the immunophenotypically defined differentia-
tion stages of the B lineage ALLs, including early pre-B, transi-1996), the identified expression profile was specific for the E2A-
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Figure 2. Correlation of gene expression analysis
with immunophenotyping of ALL
A: The expression profiles of the probe sets corre-
sponding to the immunophenotypically deter-
mined T cell-associated antigens CD2, CD3, and
CD8 and B cell-associated antigens CD19, CD22,
and CD10 across the 327 diagnostic BM samples.
T- and B-ALL cases are indicated at the top of
the figure, and the genetic subtypes are indi-
cated at the bottom. The color-coded scales for
the normalized expression values are indicated
on the bottom right of each panel. B: Represen-
tative results from immunophenotyping using
multicolor flow cytometry for detection of the
CD10 and CD19 cell surface antigens. In agree-
ment with the results of expression profiling, each
B lineage leukemia expressed a high level of
CD19, whereas expression of CD10 varied be-
tween subtypes, with no expression detected in
MLL, intermediate levels in E2A-PBX1, and high
level in TEL-AML1.
tional pre-B, and pre-B (see Supplemental Data, Tables S19– The majority of the leukemia subtype-specific genes identi-
fied through this study were not previously known to have aS21 and Figure S20 at http://www.stjuderesearch.org/data/
ALL1). Rather, the gene expression profiles of the specific ge- restricted pattern of expression (Figure 3; the list of genes se-
lected by each metric are provided in the Supplemental Datanetic subgroups always predominated.
To confirm that the microarray analysis provided an accurate at http://www.stjuderesearch.org/data/ALL1). Besides having
the potential to be used as new diagnostic and subclassificationreflection of gene expression levels, we compared the microar-
ray data with results for RNA levels obtained by real-time RT- markers, these genes provide unique insights into the underlying
biology of the different leukemia subtypes. For example, E2A-PCR (five genes) and with the corresponding protein levels as
assessed by immunophenotype analysis performed by flow cy- PBX1 leukemias were characterized by high expression of the
C-MER receptor tyrosine kinase (MERTK), a known transformingtometry (nine specific cell surface antigens). As shown in the
Supplemental Data (Figures S7–S12 and Tables S4–S9 at http:// gene (Graham et al., 1994; Georgescu et al., 1999), suggesting
that C-MER may be involved in the abnormal growth of thesewww.stjuderesearch.org/data/ALL1), a very high degree of cor-
relation was observed between the levels of RNA expression cells. Similarly, HOXA9 and MEIS1 were exclusively expressed
in cases having MLL rearrangements, indicating that they maydetected by quantitative RT-PCR and microarray analysis. Simi-
larly, in agreement with results from immunophenotying, T lin- be directly involved in MLL-mediated alterations in the growth
of the leukemic cells. Interestingly, high expression of MTG16,eage-restricted RNA expression was observed for CD2, CD3,
and CD8, whereas B lineage-restricted expression was ob- a homolog of ETO (Gamou et al., 1998), was found in TEL-
AML1 cases. Alteration of ETO family members in both t(8;21)served for CD19 and CD22 (Figure 2A and Supplemental Data,
Figure S13). In addition, the level of CD10 RNA expression acute myeloid leukemia (by translocation) (Downing, 1999) and
TEL-AML1 (by altered expression) suggests that alteration inclosely correlated with protein levels, with high expression de-
tected in TEL-AML1 leukemias, intermediate levels in E2A- the biologic function of ETO genes may be mechanistically in-
volved in these leukemias.PBX1, and low to undetectable expression in cases with re-
arrangements of MLL (Figure 2B). Thus, microarray analysis Little is known about the underlying molecular pathogenesis
of hyperdiploid ALL 50 chromosomes, which clinically is dis-provides an accurate reflection of expression levels for most
genes and can be used to accurately detect the expression tinct from hyperdiploid cases having 47–50 chromosomes. This
distinction is supported by the marked differences in gene ex-of the more common surface antigens used in the diagnostic
evaluation of pediatric ALL patients. pression profiles between these two subgroups. Although
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Figure 3. Class-defining genes for the individual leukemia subtypes
A and B: Shown are 10 of the 40 genes chosen by a chi-square statistic that are most highly correlated with each of the individual leukemia classes
indicated at the top of the panel. The GenBank accession number and the gene symbol or DNA sequence name are listed on the right side of each
panel. The color-coded scale for the normalized expression values is indicated on the bottom left. The discriminating genes for T-ALL are not shown in this
figure but are provided in the Supplemental Data at http://www.stjuderesearch.org/data/ALL1.
hyperdiploid50 ALLs have an excellent prognosis, the specific velop an expression-based leukemia classification. Through a
reiterative process of error minimization, these supervised learn-genetic lesions responsible for the aberrant proliferation in these
cases remains poorly understood. Interestingly, almost 70% of ing algorithms learn to recognize the optimal gene expression
patterns for a specific subtype. Classification was approachedthe genes that defined this subgroup were localized to either
chromosome X or 21. Moreover, the class-defining genes on using a decision tree format, in which the first decision was
T-ALL versus B lineage (non-T-ALL) and then within the B lin-chromosome X were overexpressed in the hyperdiploid 50
chromosomes ALLs irrespective of whether the leukemic blasts eage subset, cases were sequentially classified into the known
risk groups characterized by the presence of E2A-PBX1, TEL-had a trisomy of this chromosome (data not shown). Detailed
analysis will be required to determine the specific signaling AML1, BCR-ABL, MLL chimeric genes, and lastly hyperdiploid
with 50 chromosomes. Cases not assigned to one of thesepathways that are disrupted as a result of the altered expression
of these genes. Lastly, the novel subgroup of ALL was defined classes were left unassigned (see Supplemental Data, Figure
S19 at http://www.stjuderesearch.org/data/ALL1). Classifica-by high expression of a group of genes, including the receptor
phosphatase PTPRM and LHFPL2, a gene that is a part of the tion was performed using the supervised learning algorithm,
support vector machine (SVM), with a set of discriminatingLHFP-like gene family—the founding member of which was
identified as the target of a lipoma-associated chromosomal genes selected by a correlation-based feature selection (CFS)
or, if this method selected 20 genes for a particular class,translocation (Petit et al., 1999). Whether the LHFPL2 gene is
altered by a chromosomal rearrangement in these leukemias using the top 20 ranked genes selected by a chi-square metric
or one of the other metrics detailed in the Supplemental Data.remains to be determined.
As shown in Table 1, this approach resulted in exceptionally
accurate class prediction in a randomly selected training setExpression profiling as a diagnostic tool
A major goal of this study was to determine if the single platform that consisted of two-thirds of the total cases (215 cases). When
this classification model was then applied to a blinded test setof expression profiling could accurately identify the known prog-
nostically important leukemia subtypes. We formally tested this consisting of the remaining 112 samples, an overall accuracy
of 96% was achieved for class assignment (Table 1 and Supple-issue by using computer-assisted learning algorithms to de-
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Table 1. ALL subgroup prediction accuracies using support vector machine (SVM)
Training seta Test setb
Subgroups Apparent accuracyc True accuracyd Sensitivitye Specificityf
T-ALLg 100% 100% 100% 100%
E2A-PBX1 100% 100% 100% 100%
TEL-AML1 98% 99% 100% 98%
BCR-ABL 96% 97% 83% 98%
MLL rearrangement 100% 100% 100% 100%
Hyperdiploid 50 93% 96% 100% 93%
a The training set consisted of 215 samples.
b The blinded test set consisted of 112 samples.
c Apparent accuracy was determined by leave-one-out crossvalidation.
d True accuracy was determined by class prediction on the blinded test set.
e Sensitivity  (the number of positive samples predicted)/(the number of true positivies)
f Specificity  (the number of negative samples predicted)/(the number of true negatives)
g The distribution of cases in the training and test sets are: T-ALL (28 cases, 15 cases); E2A-PBX1 (18, 9); TEL-AML (52, 27); BCR-ABL (9, 6); MLL (14; 6); hyperdiploid
50 (42, 22).
mental Data, Tables S16–S18). The number of genes required pediatric ALL. Despite our success in identifying distinct leuke-
mia subtypes that have either a very high or low risk of treatmentfor optimal class assignment varied between classes. A single
gene was sufficient to give 100% accuracy for both T-ALL failure, risk assignment remains an imprecise process. To deter-
mine if expression profiling might further enhance our ability to(CD3D) and E2A-PBX1 (PBX1), whereas 7–20 genes were re-
quired for prediction of the other classes. Only slight differences identify those patients who are likely to relapse, we compared
the expression profiles of four groups of leukemic samples:were observed in the prediction accuracies of individual classes
when the process was repeated using genes selected by a (1) diagnostic samples of patients that develop hematological
relapses (n  32); (2) diagnostic samples from patients whonumber of other metrics, including T statistics, a novel metric
referred to as Wilkins’, or genes selected by a combination of remained in continuous complete remission (CCR) (n 201); (3)
diagnostic samples from patients who develop therapy-inducedself-organizing maps (SOM) and DAV (see Supplemental Data,
Tables S13–S15). Moreover, nearly identical results were ob- AML (n  16); and (4) leukemic samples collected at the time
of ALL relapse (n  25). Using DAV, distinct gene expressiontained when the various sets of selected genes were used in a
number of different supervised learning algorithms, including profiles were identified for each of these groups (Figure 4).
To further assess the predictive power of the different gene-nearest neighbor (-NN), artificial neural network (ANN), and
prediction by collective likelihood of emerging patterns (PCL) expression profiles, we again used supervised learning algo-
rithms. Because of the overwhelming differences in the expres-(see Supplemental Data, Tables S16–S18).
Importantly, the rare cases that were misclassified by gene sion profiles of the different leukemia subtypes, we were unable
to identify a single expression signature that would predict re-expression analysis were highly informative. For example, four
cases were apparently misclassified as TEL-AML1 by gene ex- lapse irrespective of the genetic subtype. However, within indi-
vidual leukemic subtypes, distinct expression profiles could bepression analysis since they lacked a detectable chimeric tran-
script by RT-PCR. However, on further analysis, one case was defined that predicted relapse. Class assignment was per-
formed using a SVM supervised learning algorithm with discrimi-shown by FISH analysis to have a TEL-AML1 fusion, presumably
a variant rearrangement that could not be detected with the nating genes selected by CFS or, if this method returned 20
genes, we used the top 20 genes selected by T statistics (Sup-amplification primers used for the TEL-AML1 RT-PCR assay
(see Supplemental Figure S21 at http://www.stjuderesearch. plemental Tables S22–S24 at http://www.stjuderesearch.org/
data/ALL1). As shown, for both the T-ALL and hyperdiploid50org/data/ALL1). In the other three cases, reexamination of the
karyotypes revealed translocations involving the p arm of chro- subgroups, expression profiles identified those cases that went
on to relapse with an accuracy of 97% and 100%, respectively,mosome 12 in each case. By FISH analysis, two of these cases
had deletion of one TEL allele, whereas the remaining case had by crossvalidation. Moreover, these prediction accuracies were
statistically significant when compared to results from an analy-a partial deletion of one TEL allele (see Supplemental Data,
Figure S21). Thus, the identified expression profiles appear to sis of 1000 random permutations of the specific patient data
set (Figure 5A and Supplemental Data). Similarly, expressionreflect an abnormality of the TEL transcription factor and may
provide a more accurate means of identifying a specific leukemia profiles predictive of relapse were identified for TEL-AML, MLL,
or cases that lacked any of the known genetic risk featuressubtype defined by its underlying biology. Collectively, these
data suggest that the single platform of gene expression profil- (Supplemental Data, Table S25). However, although the pre-
dictive accuracies of these latter expression profiles were verying can accurately identify the known prognostic subtypes of
ALL. high by crossvalidation, they did not reach statistical signifi-
cance when compared to results from an analysis of 1000 ran-
dom permutations of the same patient data set, likely secondaryUse of expression profiles to identify patients
at high risk of treatment failure to the limited number of cases. The expression signatures pre-
dictive of relapse for T-ALL and hyperdiploid 50 ALLs areRelapse and the development of therapy-induced acute myeloid
leukemia (AML) are the major causes of treatment failure in shown in Figures 5B and 5C. A key point is that no single gene
138 CANCER CELL : MARCH 2002
A R T I C L E
overexpression of these genes is mechanistically involved in
the increased risk of therapy-induced AML or is only a chance
association remains to be determined. Formal proof of the pre-
dictive value of this identified expression signature will require
confirmation in an independent group of patients.
Discussion
Contemporary approaches to the diagnosis of pediatric ALL
requires an extensive range of procedures including morphol-
ogy, immunophenotyping, cytogenetics, and molecular diag-
nostics. Using gene expression profiling, we now demonstrate
that the single platform of microarray expression analysis can
accurately identify each of the known prognostically and thera-
peutically relevant subgroups of childhood ALL. Distinct gene
expression profiles were identified for ALL blasts with T lineage,
hyperdiploid 50 chromosomes, BCR-ABL, E2A-PBX1, TEL-
AML1, and MLL gene rearrangement. In addition, using a variety
of computer-assisted supervised learning algorithms, overall
diagnostic accuracies of 96% were achieved. This level of accu-
racy exceeds that typically achieved using contemporary diag-
nostic approaches in most medical centers. Moreover, the as-
Figure 4. The expression profiles of diagnostic blasts from patients that are signment of a leukemic sample to a specific biologic subgroup
cured versus those that relapse or develop secondary AML are distinct
may be more accurately reflected by its gene expression profile
Multidimensional scaling plot of the gene expression data from 16 diagnos- than by the presence or absence of a specific genetic lesion.
tic (Dx) samples from patients who developed secondary AML (2nd AML),
This is best exemplified by four cases that had expression pro-32 Dx samples from patients who developed a hematological relapse, 201
files classified as TEL-AML1 despite lacking a TEL-AML1 chime-Dx samples from patients who remained in continuous complete remission
(CCR), and 25 BM or PB samples at the time of ALL relapse (relapsed ALL). ric message by RT-PCR. As noted, each of these cases was
Each case is represented by a sphere and is color-coded as indicated. The found to have an alteration in TEL, suggesting a common under-
individual dimensions represent linear combinations of genes. The DAV was
lying biology. Thus, from a technical viewpoint, gene expressionperformed using all 11,322 probe sets that passed the variation filter and
profiling should be a viable alternative to standard diagnosticthe displayed gene space represents the total variance within this data
set. approaches. Whether gene expression profiling will become a
practical diagnostic alternative remains to be determined. It is
important to stress, however, that once a diagnostic algorithm
using a defined set of genes is established, its routine use in a
can be used to predict the risk of relapse. Rather, patterns clinical setting will require only minimal expertise. As the cost
of expression for a combination of genes were found to be of gene expression profiling decreases, this type of analysis
predictive. Since few known risk-stratifying biologic features will likely become highly competitive when compared to the
have been previously identified for either T-ALL or hyperdiploid cumulative cost of the various diagnostic studies that are pres-
50 ALL, our results suggest that the identified expression ently used.
profiles provide independent risk-stratifying information. One of the most surprising observations from this study
A provocative observation was the identification of a distinct was the remarkable difference in the expression profiles of the
expression profile in the ALL blasts from those patients who individual leukemia subtypes. Despite having relatively homoge-
developed therapy-induced AML. Because secondary AML is nous morphology and limited variability in the extent of T or B cell
thought to arise from a hematopoietic stem cell that is distinct differentiation, each leukemia subtype had a distinct expression
from that giving rise to the primary leukemia (Figure 6A), it is profile that involved a large number of genes. These observa-
difficult to understand how the biology of the original ALL blasts tions are in agreement with a more limited study in which the
could predict the risk of developing a therapy-induced compli- expression profiles of ALLs with MLL rearrangements were
cation. Nevertheless, we formally evaluated the accuracy of shown to differ from those of other acute leukemias (Armstrong
expression profiling in identifying these patients. Again, no sin- et al., 2001). Remarkably, the expression differences between
individual ALL subtypes were more robust than expression dif-gle expression profile was identified that worked across the
different leukemia subgroups. However, within the TEL-AML1 ferences between either lung adenocarcinoma (Su et al., 2001)
or melanoma (Ramaswamy et al., 2001) and bladder transitionalsubgroup, a distinct expression signature consisting of 20 genes
was defined that identified, with 100% accuracy in crossvalida- carcinoma, tumors that conceptually would be considered more
divergent. Thus, our data supports the interpretation that thesetion, all patients who developed secondary AML, with a p value
of 0.031 as assessed by comparison to results from an analysis leukemic subtypes are distinct biological and clinical entities.
For subgroups defined by either translocation-encoded chime-of 1000 random permutations of the patient data set (Figure
6B). Genes within this signature included RSU1, a suppressor ric transcription factors or altered signaling proteins such as
BCR-ABL, the presence of a distinct gene expression profile isof the RAS signaling pathway, and MSH3, a mismatch repair
enzyme (Figure 6C and Supplemental Data, Tables S26 and not completely unexpected. By contrast, the identification of a
unique expression profile for novel ALL cases with50 chromo-S27 at http://www.stjuderesearch.org/data/ALL1). Whether the
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Figure 5. Gene expression profiles as predictors of relapse
A: Genes predictive of the class distinction relapse versus continuous complete remission (CCR) for either T-ALL or hyperdiploid 50 ALL (HD) were chosen
by CFS or T statistics. The selected genes were then used in a SVM supervised learning algorithm, and performance was assessed by a crossvalidation
experiment. The apparent accuracies of prediction are indicated. The significance of the prediction accuracy was determined by performing 1000
permutation experiments for each subtype-specific group (see Supplemental Data at http://www.stjuderesearch.org/data/ALL1). The percentage of these
1000 random partitions that gave a prediction accuracy equal to or better than that for the relapse prediction was taken as a p value. B and C: The
expression pattern of the 7 and 20 genes that were selected as discriminators of relapse versus CCR in T-ALL and HD cases, respectively. The GenBank
accession number and the gene symbol or DNA sequence name are listed on the right side of each panel.
somes is surprising. Examination of the expression profiles of ultimately converge on these critical functions. Clearly, some
of the identified expression differences result from variationshyperdiploid 50 and the ALL subgroup identified here should
provide important new insights into the underlying pathogenesis in lineage or stage of differentiation. What proportion of the
remaining expression changes are mechanistically involved inof these leukemic subtypes. The expression profiles of these
and the other leukemia subtypes has not only provided insights transformation remains to be determined. Similarly, determining
how the identified expression differences are involved in theinto their biology but has also resulted in the identification of a
number of genes that should prove useful as markers to monitor unique clinical biology of the leukemias, including their distinc-
tive responses to particular types of chemotherapy, remains topatients for minimal residual disease. In addition, some of the
identified genes, such as the C-MER receptor tyrosine kinase be defined.
One of the most promising aspects of gene expression pro-in E2A-PBX1, may prove to be useful targets against which
novel therapeutic agents could be developed. filing is the hope that it will improve the ability to accurately
identify those patients who are at a high risk of failing conven-The marked differences seen in the expression profiles of the
various ALL subtypes suggest that transformation may occur tional therapy. Strikingly, our results demonstrate that the gene
expression profiles differ between the diagnostic samples ofthrough distinct pathways. Although only a limited number of
growth control mechanisms need to be subverted to result in patients who relapse and those who remain in continuous com-
plete remission. Moreover, specific expression profiles in thecellular transformation (Hanahan and Weinberg, 2000), our data
suggest that in pediatric ALL, multiple pathways may exist and diagnostic samples of either T-ALL or hyperdiploid ALL appear
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Figure 6. A gene expression profile that predicts the development of secondary AML in TEL-AML1 ALL
A: Schematic illustration showing that therapy-induced AML (2nd AML) is believed to arise from a hematopoietic progenitor that is distinct from the one
that gave rise to the original ALL leukemic clone. B: Genes within the diagnostic ALL BM samples that were predictive of development of therapy-induced
AML were selected by their MIT score and then used in a SVM supervised learning algorithm. Performance was assessed by a crossvalidation experiment,
and the results are indicated as apparent accuracy. The significance of the prediction accuracy was determined by performing 1000 random permutation
experiments, with the p value indicating the percentage of these random experiments that gave a prediction accuracy equal to or better than the
secondary AML prediction. C: The expression profile of a subset of the genes selected as predictors of the development of secondary AML in TEL-AML1-
positive ALLs. The GenBank accession number and the gene symbol or DNA sequence name are listed on the right of the panel.
to be accurate predictors of relapse. Although these data will within the human genome (Hogenesch et al., 2001). In the future,
the use of higher-density chips should not only further enhanceneed to be validated in prospective studies, these findings raise
the expectation that, in the future, this type of analysis will be our ability to accurately identify those patients who will relapse,
but should also provide a clearer view of the underlying biology.used to make therapeutic decisions. In addition, the identified
expression profiles should provide critical insights into the un- The provocative finding of an expression profile in the diag-
nostic samples that identifies patients who subsequently devel-derlying mechanisms that contribute to relapse. The observation
that we could not identify a common expression profile that oped therapy-induced AML will need to be validated in an inde-
pendent cohort of patients. Although a distinct expressionpredicted relapse irrespective of the genetic subtype suggests
that a unifying mechanism of relapse may not exist. Rather, profile was defined that identified those TEL-AML1 ALL patients
who developed secondary AML, it remains to be determined ifmechanisms of relapse or drug resistance may differ among
leukemia subtypes. Alternatively, the identified expression pro- the profile represents genes that are mechanistically involved
in the enhanced risk or are only statistical associations. Reas-files may consist of genes that are chance associations with
pending relapse and not genes directly involved in the underly- sessment of these samples using higher-density chips will allow
a significantly broader view of the genes that characterize theing biology. It is important to keep in mind that the present
analysis falls far short of a total transcriptional profile of the ALL blasts of patients who develop secondary AML and may
thereby help to answer this question. Despite these caveats,leukemic blasts. Although 12,600 probe sets are present on
the microarray, the total number of genes that this represents these findings suggest the concept that expression profiling of
leukemic blasts, and possibly nonmalignant hematopoieticaccounts for less than 20% of the estimated number of genes
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Palo Alto, CA). cDNA was synthesized using a T-7 linked oligo-dT primer,cells, may enhance our ability to identify patients who are at a
and cRNA was then synthesized with biotinylated UTP and CTP. The labeledhigh risk of developing therapy-induced complications, includ-
RNA was then fragmented and hybridized to HG_U95Av2 oligonucleotideing secondary malignancies, severe organ toxicities, and infec-
arrays (Affymetrix Incorporated, Santa Clara, CA) according to Affymetrix
tions. protocols.
Two recent studies have presented results from a more Arrays were scanned using a laser confocal scanner (Agilent), and the
limited analysis of the expression profiles of pediatric ALLs (Arm- expression value for each gene was calculated using Affymetrix Microarray
software v.4.0. The average intensity difference (AID) values were normalizedstrong et al., 2001; Ferrando et al., 2002). Although there is
across the sample set, and minimum quality control standards were estab-a high degree of correlation between our results and those
lished for including a sample’s hybridization data in the study (see Supple-presented in these other studies, subtle differences are evident.
mental Data at http://www.stjuderesearch.org/data/ALL1). To ensure consis-
Foremost is the observation that not all MLL discriminating tency of data acquisition throughout the study, 10% of samples were run
genes identified in the Armstrong paper were found to distin- in duplicate. An exceedingly high reproducibility was observed between
guish this ALL subtype in our analysis. Using a much larger replicate samples, with less than 1% of genes having a variation in average
intensity difference (AID) of2-fold. The primary hybridization data are avail-number of cases, we find that some of the genes that were
able at our website (http://www.stjuderesearch.org/ALL1).originally found to correlate with MLL in fact have a broader
expression pattern than was originally appreciated. Similarly, in
Statistical analysis
T-ALL, by using a much larger number of genes to assess the Unsupervised hierarchical clustering, principal component analysis (PCA),
expression profiles, we now find prognostic markers that were discriminant analysis with variance (DAV), and self-organizing maps (SOM)
not identified in the study of Ferrando. were performed using GeneMaths software (v.1.5, Applied Maths, Belgium).
Data reduction to define the genes most useful in class distinction wasIn summary, contemporary risk stratification requires a com-
performed using a variety of metrics as detailed in the Supplemental Databination of methodologies and fails to identify many patients
at http://www.stjuderesearch.org/data/ALL1. Genes selected by the variouswho are at high risk of drug-induced toxicities. The data pre-
metrics were used in supervised learning algorithms to build classifiers that
sented here suggest that the single platform of gene expression could identify the specific genetic or prognostic subgroups. Algorithms used
profiling provides a robust and accurate approach for the diag- included k-nearest neighbors (k-NN), support vector machine (SVM), predic-
nosis and risk stratification of pediatric ALL patients. Moreover, tion by collective likelihood of emerging patterns (PCL), an artifical neural
network (ANN), and weighted voting. Performance of each model was initiallythis approach should enhance our ability to identify patients
assessed by leave-one-out crossvalidation on a randomly selected stratifiedwho are at a high risk of developing marrow relapse and drug-
training set consisting of two-thirds of the total cases. True error rates ofrelated toxicities. In the future, development of custom diagnos-
the best-performing classifiers were then determined using the remaining
tic chips containing those genes that define both prognostically third of the samples as a blinded test group. Details of the individual metrics
important leukemia subtypes as well as a patient’s relative risks and supervised learning algorithms are described in the Supplemental Data.
to relapse or develop therapy-induced AML would significantly
Supplemental dataadvance our ability to individualize therapy so that each patient
Additional information on the samples, methods, statistical analysis, andhas the highest chance for cure. Lastly, the generated database
results from the comparison of microarray gene expression levels with mRNAof comprehensive gene expression profiles coupled with de-
levels determined by real time RT-PCR or antigen levels determined by flow
tailed immunophenotype, cytogenetic, molecular diagnostic, cytometry are available in the Supplemental Data at http://www.
and treatment outcome data should be an invaluable resource stjuderesearch.org/data/ALL1.
for studies of pediatric leukemia.
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